CSPC subsidiary wins China approval for diabetes drug

CSPC Baike (Shandong) Biopharmaceutical Co., a subsidiary of CSPC Pharmaceutical Group, announced that China's National Medical Products Administration has accepted its application for marketing approval of Semaglutide Injection for adult type 2 diabetes patients.

The Class 2.2 new drug showed high consistency in efficacy and fewer gastrointestinal reactions compared to Novo Nordisk's semaglutide in Phase III trials. The company is also advancing Phase III trials for obesity and overweight indications.